US FDA reviewers skeptical of Novartis' easier-to-use tobramycin
This article was originally published in Scrip
Executive Summary
Although Novartis' inhalation powder form of tobramycin, dubbed TIP, is faster, simpler and more portable to use for patients with cystic fibrosis (CF) infected with the bacterium Pseudomonas aeruginosa, US FDA drug reviewers were skeptical it works as well as the company's already approved inhalation solution form of the medicine, known as TOBI.